Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks
- 1 April 1999
- journal article
- review article
- Published by Elsevier in Trends in Biotechnology
- Vol. 17 (4) , 169-174
- https://doi.org/10.1016/s0167-7799(98)01291-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Viral vectors for gene therapyTrends in Biotechnology, 1998
- The TMC Worldwide Gene Therapy Enrollment Report, End 1996. Report of TMC Development, Paris, FranceHuman Gene Therapy, 1997
- High-Yield Production of pBR322-Derived Plasmids Intended for Human Gene Therapy by Employing a Temperature-Controllable Point MutationHuman Gene Therapy, 1996
- Direct Gene Transfer for Treatment of Human CancerAnnals of the New York Academy of Sciences, 1995
- Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical ProductsHuman Gene Therapy, 1995
- Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical TrialsHuman Gene Therapy, 1995
- Bacterial Lipopolysaccharide Copurifies with Plasmid DNA: Implications for Animal Models and Human Gene TherapyHuman Gene Therapy, 1995
- Human gene therapyScience, 1992
- Strategies for improving plasmid stability in genetically modified bacteria in bioreactorsTrends in Biotechnology, 1991
- Purity analysis of protein pharmaceuticals produced by recombinant DNA technologyTrends in Biotechnology, 1989